Association of Inflammatory and Hemostatic Markers With Stroke and Thromboembolic Events in Atrial Fibrillation: A Systematic Review and Meta-analysis

Canadian Journal of Cardiology

Volumn 31, Issue 3, 2015, Pages 278-286

  Wu, Na ^a   Chen, Xinghua ^a   Cai, Tongjian ^a   Wu, Long ^a   Xiang, Ying ^a   Zhang, Mengxuan ^a   Li, Yafei ^a   Song, Zhiyuan ^a   Zhong, Li ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; D DIMER; INTERLEUKIN 6; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PEPTIDE HYDROLASE; SELECTIN; SERINE PROTEINASE INHIBITOR;

ADVERSE OUTCOME; CARDIAC PATIENT; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE VOLUME; THROMBOEMBOLISM; ATRIAL FIBRILLATION; BLOOD; COMPLICATION; METABOLISM; MORTALITY; SENSITIVITY AND SPECIFICITY; STROKE;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ANTITHROMBIN III; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INTERLEUKIN-6; MEAN PLATELET VOLUME; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SELECTINS; SENSITIVITY AND SPECIFICITY; SERINE PROTEINASE INHIBITORS; STROKE; THROMBOEMBOLISM; VON WILLEBRAND FACTOR;

EID: 84923922872     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.12.002     Document Type: Review

References (51)

1. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. JAm Coll Cardiol 2011, 57:e101-e198.
2. Heeringa J., Conway D.S., van der Kuip D.A., et al. Alongitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. JThromb Haemost 2006, 4:1944-1949.
3. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
4. Chugh S.S., Blackshear J.L., Shen W.K., Hammill S.C., Gersh B.J. Epidemiology and natural history of atrial fibrillation: clinical implications. JAm Coll Cardiol 2001, 37:371-378.
5. Brugts J.J., Akin S., Helming A.M., Loonstra S., van den Bos E.J., Kofflard M.J. The predictive value of cardiac biomarkers in prognosis and risk stratification of patients with atrial fibrillation. Curr Opin Cardiol 2011, 26:449-456.
6. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
7. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.
8. Kornej J., Apostolakis S., Bollmann A., Lip G.Y. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol 2013, 29:1181-1193.
9. Kumagai K., Fukunami M., Ohmori M., et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. JAm Coll Cardiol 1990, 16:377-380.
10. Soncini M., Casazza F., Mattioli R., et al. Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation. Minerva Med 1997, 88:501-505.
11. Zabczyk M., Majewski J., Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Med Wewn 2011, 121:400-407.
12. Loffredo L., Violi F., Fimognari F.L., et al. The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica 2005, 90:1205-1211.
13. Topcuoglu M.A., Haydari D., Ozturk S., Ozcebe O.I., Saribas O. Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation. Neurol Sci 2000, 21:235-240.
14. Alonso A., Tang W., Agarwal S.K., et al. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol 2012, 155:217-222.
15. Hermida J., Lopez F.L., Montes R., et al. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol 2012, 109:95-99.
16. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
17. Little J., Bradley L., Bray M.S., et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002, 156:300-310.
18. Wells GA, Shea B, O'Connell D, etal. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at:. Accessed July 20,2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
20. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.
21. Liu T., Li G., Li L., Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. JAm Coll Cardiol 2007, 49:1642-1648.
22. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
23. Ha S.I., Choi D.H., Ki Y.J., et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets 2011, 22:408-414.
24. Sadanaga T., Kohsaka S., Ogawa S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology 2010, 117:31-36.
25. Sadanaga T., Sadanaga M., Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. JAm Coll Cardiol 2010, 55:2225-2231.
26. Pinto A., Tuttolomondo A., Casuccio A., et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009, 116:781-789.
27. Nozawa T., Inoue H., Hirai T., et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006, 109:59-65.
28. Conway D.S., Buggins P., Hughes E., Lip G.Y. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004, 148:462-466.
29. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107:3141-3145.
30. Feinberg W.M., Pearce L.A., Hart R.G., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999, 30:2547-2553.
31. Roldan V., Marin F., Gallego P., Vicente V., Lip G.Y. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal. JThromb Haemost 2012, 10:2414-2415.
32. Christersson C., Wallentin L., Andersson U., et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation-observations from the ARISTOTLE trial. JThromb Haemost 2014, 12:1401-1412.
33. Ertas G., Sonmez O., Turfan M., et al. Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. JNeurol Sci 2013, 324:49-52.
34. Skov J., Sidelmann J.J., Bladbjerg E.M., Jespersen J., Gram J. Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation. Thromb Res 2014, 134:717-722.
35. Turfan M., Erdogan E., Ertas G., et al. Usefulness of mean platelet volume for predicting stroke risk in atrial fibrillation patients. Blood Coagul Fibrinolysis 2013, 24:55-58.
36. Cecchi E., Marcucci R., Poli D., et al. Hyperviscosity as a possible risk factor for cerebral ischemic complications in atrial fibrillation patients. Am J Cardiol 2006, 97:1745-1748.
37. You L., Wang P., Lv J., et al. The role of high-sensitivity C-reactive protein, interleukin-6 and cystatin C in ischemic stroke complicating atrial fibrillation. JHuazhong Univ Sci Technolog Med Sci 2010, 30:648-651.
38. Roldan V., Marin F., Blann A.D., et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003, 24:1373-1380.
39. Kahn S.R., Solymoss S., Flegel K.M. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ 1997, 157:673-681.
40. Pongratz G., Brandt-Pohlmann M., Henneke K.H., et al. Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation. Chest 1997, 111:929-933.
41. Black I.W., Chesterman C.N., Hopkins A.P., et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. JAm Coll Cardiol 1993, 21:451-457.
42. Gustafsson C., Blomback M., Britton M., Hamsten A., Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990, 21:47-51.
43. Brotman D.J., Deitcher S.R., Lip G.Y., Matzdorff A.C. Virchow's triad revisited. South Med J 2004, 97:213-214.
44. Choudhury A., Lip G.Y. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb 2003, 33:282-289.
45. Danese E., Montagnana M., Cervellin G., Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. Ann Med 2014, 46:364-371.
46. Karthikeyan G., Eikelboom J.W. The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe?. Thromb Haemost 2010, 104:45-48.
47. Hijazi Z., Wallentin L., Siegbahn A., et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. JAm Coll Cardiol 2014, 63:52-61.
48. Hijazi Z., Wallentin L., Siegbahn A., et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). JAm Coll Cardiol 2013, 61:2274-2284.
49. Lip G.Y., Lane D., Van Walraven C., Hart R.G. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006, 37:2294-2300.
50. Griffiths HR, Lip GY. New biomarkers and risk stratification inatrial fibrillation: simplicity and practicality matter. Circulation 2014;130:1837-9.
51. Lau J., Ioannidis J.P., Terrin N., Schmid C.H., Olkin I. The case of the misleading funnel plot. BMJ 2006, 333:597-600.